Vedanta Biosciences receives $50M for microbiome therapeutics — 5 points

Cambridge, Mass.-based Vedanta Biosciences raised $50 million in new equity investments for its therapies to modulate the human microbiome.

Here are five points:

1. The new investors include Rock Springs Capital, Invesco Asset Management, Health for Life Capital and PureTech.

2. Vedanta Biosciences will use the funding for its clinical studies in infectious and autoimmune diseases.

3. The financing will also help with developing the company's technology platform.

4. Vedanta Biosciences has already isolated human-associated bacterial strains as well as characterized how the immune system recognizes and responds to microbes.

5. The company has identified drug candidates composed of defined bacterial consortia, for infectious disease, immune tolerance, inflammation and immuno-oncology.

More articles on quality & infection control:
Former surgical tech tests HIV positive; compromises 1.5k patients: 5 key points
6 steps to create & maintain an outstanding ASC infection control program
Electronic monitoring increases hand hygiene compliance: 5 observations

© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 


Patient Safety Tools & Resources Database

Top 40 Articles from the Past 6 Months